MedTrace Logo

Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF

NCT05330312 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2024-09-24

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess efficacy and safety of a digital cognitive behavioural therapy for patients with pulmonary fibrosis on anxiety.

Conditions

Interventions

DEVICE

Digital cognitive behavioral therapy

Therapy for patients with pulmonary fibrosis

Sponsors & Collaborators

  • Curebase Inc.

    collaborator INDUSTRY

  • Vicore Pharma AB

    lead INDUSTRY

Principal Investigators

  • Maureen Horton, MD · Curebase study site

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-17
Primary Completion
2023-10-19
Completion
2023-11-10
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05330312 on ClinicalTrials.gov